DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Hereditary Angioedema (HAE)” report has been added
to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Hereditary Angioedema market,
comprising key pipeline and marketed drugs, clinical trials, upcoming
and regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals, as well as presenting
drug-specific revenue forecasts
Key Takeaways
-
The report estimates that in 2017, there were approximately 402,700
prevalent cases of hereditary angioedema worldwide, and forecasts that
number to increase to 440,600 prevalent cases by 2026. -
The approved drugs in the hereditary angioedema space target
complement proteins, androgen receptors, follicle-stimulating hormone,
gonadotropin-releasing hormone, progesterone receptor, bradykinin B2
receptor, and the kinin-kallikrein system. These are commonly
administered via the intravenous or subcutaneous routes, with one
product being available in an oral formulation. -
There are only seven drugs in active clinical development for
hereditary angioedema, with five drugs in Phase I and two in Phase III. -
Therapies in mid-to-late-stage development for hereditary angioedema
focus on targets such as the kinin-kallikrein system and complement
proteins. These drugs are administered via the subcutaneous and oral
routes. -
High-impact upcoming events for drugs in the hereditary angioedema
space comprise topline Phase III trial results for BCX7353, topline
Phase II trial results for KVD900, and a data exclusivity expiration
for Ruconest. -
The overall likelihood of approval of a Phase I
autoimmune/immunology-other asset is 20.7%, and the average
probability a drug advances from Phase III is 69.4%. Drugs, on
average, take 9.7 years from Phase I to approval, compared to 8.7
years in the overall autoimmune/immunology space. -
There have been only three licensing and asset acquisition deals
involving hereditary angioedema drugs during 2014-19. The $125m
licensing agreement signed in 2016 between Pharming and Bausch Health,
for the acquisition of North American commercialization rights for
Ruconest, was the largest deal during the period. -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials for hereditary angioedema have been in the late
phases of development, with 55% of trials in Phase III-IV, and 45% in
Phase I-II. -
The US has a substantial lead in the number of hereditary angioedema
clinical trials globally. The UK leads the major EU markets, while
Israel has the top spot in Asia. -
Clinical trial activity in the hereditary angioedema space is
dominated by completed trials. Takeda has the highest number of
completed trials for hereditary angioedema, with 25 trials. -
Takeda leads industry sponsors with the highest number of clinical
trials for hereditary angioedema, followed by BioCryst.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
C1-INH concentrates
Plasma-derived C1-INH (pdC1-INH)
Recombinant C1-INH (rhC1-INH)
Kallikrein inhibitor
Bradykinin receptor antagonist
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
BCX7353 for Hereditary Angioedema (September 4, 2018)
Cinryze (SQ) for Hereditary Angioedema (September 11, 2017)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
Takhzyro Among Hopefuls For EU Approval Recommendation
Takhzyro Approved For HAE Attacks With Nearly Spotless Label
With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From
CSL Behring
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
BioCryst Changes Mind On Idera Merger
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/45kepf
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs